Alterity Therapeutics(US:ATHE) Globenewswire·2026-01-21 12:25Core Insights - Alterity Therapeutics has successfully completed its Phase 2 program for ATH434 in multiple system atrophy (MSA), demonstrating safety and efficacy, and is now preparing for Phase 3 trials [1][2][5] Company Developments - The Phase 2 trials showed ATH434 to be safe and well-tolerated, with significant efficacy signals in a market with no current disease-modifying treatments, representing a potential $2.4 billion opportunity [2][5] - The company is focused on advancing ATH434 towards a pivotal Phase 3 clinical program and is set to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize trial design [8][14] - Alterity has strengthened its leadership team, appointing Julian Babarczy as Chair of the Board and enhancing its governance structure to support growth [12][13] Clinical and Scientific Progress - ATH434 has shown promising results in slowing disease progression across various clinical endpoints, including functional measures and symptoms of orthostatic hypotension [5][11] - The company has deepened its understanding of MSA biology through biomarker and imaging studies, reinforcing the role of dysregulated brain iron and α-synuclein pathology [6][7] Future Objectives - The company aims to finalize its regulatory strategy for the Phase 3 trial, deepen engagement with the medical community, and build for scalable growth, including expanding intellectual property protection [18]